Title: Critical On-Study Biomarker KPIs for Modern Trials – Part 2: Integrating Data Silos to Unlock Scientific Insights and Empower Translational Teams
Duration: 45 minutes
You will learn how to:
- Expand your use of exploratory biomarker data in combination with clinical metadata for on-study analytics
- Centralize integrated biomarker and clinical data as a single source of truth to expedite drug development decisions and enable translational exploration
- Leverage dashboards to support collaboration and quickly surface actionable insights
Abstract of the Webinar
Today’s clinical trials have global footprints to reach targeted patient populations and rely on specialty labs running complex assays to assess safety, characterize patient response, and provide insight into efficacy. These biomarker-centric programs demand a focused strategy to provide timely visibility into sample availability and quality, data availability and quality, and critical on-study measurements.
Much of the information necessary to deliver translational intelligence exists today – though it is dispersed across workstreams (e.g. sample, assay, clinical, consent) and stakeholders (e.g. CROs, sites, labs, sponsors) and systems (e.g. EDC, CTMS, LIMS). Just as EDC adoption accelerated the centralization of clinical data, our team will highlight the opportunity to integrate and centralize biomarker data, the unique challenges that have historically faced the industry, and how overcoming these challenges can unlock transformative insights.
In Part 2 of our webinar series, “Integrating Data Silos to Unlock Scientific Insights and Empower Translational Teams,” we will discuss the opportunity to expand the use of exploratory data for on-study insights. Topics to be covered include:
- Centralizing integrated biomarker and clinical data as a single source of truth to enable insights into PK/PD effects as well as translational exploration
- Leveraging dashboards to support collaboration and quickly surface actionable insights
Throughout the discussions, our team will highlight how smart technology, consisting of sophisticated connectors and scalable data workflows, enables the rapid assimilation and synthesis of historically disparate data. This use of technology enables insights today – rather than as the product of years long enterprise investments – and reduces the burden, frustrations, and delays associated with manual data reconciliation and a patchwork of homegrown solutions.
If you missed Part 1: Centralizing PK, Clinical, and Exploratory Data to Streamline Biomarker-Centric Trial Operations, we cover logistical challenges (many exacerbated by the pandemic) that have sharpened our industry’s focus on data centralization to ensure today’s investments in biomarker-guided clinical trials yield the volume, quality, and depth of data needed to advance translational research.
About the Speaker:
Tobi Guennel, Ph.D.
|QuartzBio, part of Precision for Medicine, is providing a technology enabled next-generation data science solution for virtual Sample Inventory Management, Biomarker Data Management and Computational Biology to solve the challenges with the goal to accelerate drug development. As the Chief Architect of our Data Integration and Informatics Platform, Tobi Guennel strives to develop innovative technology solutions to support life science companies in their quest to improve patient care and outcomes.|